Newman Dignan & Sheerar Inc. Trims Stake in Merck & Co., Inc. $MRK

Newman Dignan & Sheerar Inc. lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 34.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,420 shares of the company’s stock after selling 15,275 shares during the quarter. Newman Dignan & Sheerar Inc.’s holdings in Merck & Co., Inc. were worth $3,097,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Cliftonlarsonallen Wealth Advisors LLC increased its stake in Merck & Co., Inc. by 3.6% in the 4th quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 35,206 shares of the company’s stock worth $3,706,000 after buying an additional 1,237 shares during the period. Sutton Place Investors LLC increased its stake in Merck & Co., Inc. by 13.7% in the 4th quarter. Sutton Place Investors LLC now owns 6,054 shares of the company’s stock worth $637,000 after buying an additional 728 shares during the period. Jackson Square Capital LLC purchased a new position in Merck & Co., Inc. in the 4th quarter worth about $1,021,000. Franklin Street Advisors Inc. NC increased its stake in Merck & Co., Inc. by 462.8% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 142,541 shares of the company’s stock worth $15,004,000 after buying an additional 117,213 shares during the period. Finally, Woodmont Investment Counsel LLC increased its stake in Merck & Co., Inc. by 1.9% in the 4th quarter. Woodmont Investment Counsel LLC now owns 170,507 shares of the company’s stock worth $17,948,000 after buying an additional 3,189 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck launched a cash tender offer to buy Terns Pharmaceuticals, accelerating an acquisition that expands its oncology and hematology pipeline ahead of patent expiries for key products — a strategic move that can support future revenue. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Positive Sentiment: JPMorgan and other analysts have raised price targets / reiterated Overweight views on MRK, signaling institutional confidence that Merck shares still have upside — a catalyst for buying interest. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
• Positive Sentiment: Merck’s recent quarterly results beat estimates, revenue grew year-over-year and the company set FY2026 EPS guidance — underpinning valuation and investor confidence in near-term fundamentals. Strong Results Lifted Merck & Co (MRK) in Q4
• Positive Sentiment: Merck is highlighted among consistent dividend stocks, which can attract income-focused and defensive investors amid market uncertainty. Is Merck & Co. (MRK) One of the Best Consistent Dividend Stocks to Buy Right Now?
• Neutral Sentiment: Merck lowered its offer price for Terns after reviewing trial data, a detail that changes deal economics and signals the firm is calibrating cost vs. risk — ambiguous for MRK shareholders (lower cash outlay vs. potential pipeline concerns). Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
• Neutral Sentiment: Coverage pieces are reassessing Merck’s valuation after strong price momentum; momentum supports higher multiples, but some analysts flag S&P 500 reweighting and valuation headwinds. Assessing Merck (MRK) Valuation After Strong Recent Share Price Momentum
• Neutral Sentiment: Analysis explains the Terns deal’s role in Merck’s pipeline and how it could affect S&P 500 valuation exposure — useful context but not an immediate share-mover. Merck’s (NYSE:MRK) Terns Deal And S&P 500 Valuation Impact Explained
• Negative Sentiment: Some intraday weakness was reported recently as the broader market improved — a reminder that short-term pullbacks can occur even with positive headlines. Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
• Negative Sentiment: Commentary questioning whether Merck is overbought warns of near-term valuation risk after a big run — a potential headwind for momentum traders. Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Merck & Co., Inc. Stock Up 3.3%

Shares of NYSE MRK opened at $123.25 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $304.73 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The stock’s fifty day simple moving average is $118.54 and its two-hundred day simple moving average is $104.06. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.’s payout ratio is 46.70%.

Insider Activity

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at $52,362,780.08. This represents a 9.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 over the last 90 days. 0.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research analyst reports. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $82.00 to $130.00 in a research report on Thursday, December 18th. Bank of America lifted their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a research note on Thursday, January 8th. Finally, UBS Group upped their price objective on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $127.59.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.